S&P 500   4,207.27
DOW   33,336.67
QQQ   324.08
Find and Profitably Trade Stocks at 52-Week Lows
Average 126% gains – NO losers!?   (Ad)pixel
Why Invest in High-Yield Dividend Stocks?
The 2 Dow Stocks with Decade-Long Win Streaks on the Line
3 Stable Growth Stocks for Bumpy Times
27 U.S. Cities Where Stocks Yield 26% a Year (Ad)pixel
Disney (NYSE: DIS) Shares Just Gave Investors A Massive Signal
Solar Stocks Shine Brightly After Passage Of Clean Energy Bill
Large And Small Oil-And-Gas Stocks See Post-Earnings Bounce
One Stock Is All You Need  (Ad)pixel
S&P 500   4,207.27
DOW   33,336.67
QQQ   324.08
Find and Profitably Trade Stocks at 52-Week Lows
Average 126% gains – NO losers!?   (Ad)pixel
Why Invest in High-Yield Dividend Stocks?
The 2 Dow Stocks with Decade-Long Win Streaks on the Line
3 Stable Growth Stocks for Bumpy Times
27 U.S. Cities Where Stocks Yield 26% a Year (Ad)pixel
Disney (NYSE: DIS) Shares Just Gave Investors A Massive Signal
Solar Stocks Shine Brightly After Passage Of Clean Energy Bill
Large And Small Oil-And-Gas Stocks See Post-Earnings Bounce
One Stock Is All You Need  (Ad)pixel
S&P 500   4,207.27
DOW   33,336.67
QQQ   324.08
Find and Profitably Trade Stocks at 52-Week Lows
Average 126% gains – NO losers!?   (Ad)pixel
Why Invest in High-Yield Dividend Stocks?
The 2 Dow Stocks with Decade-Long Win Streaks on the Line
3 Stable Growth Stocks for Bumpy Times
27 U.S. Cities Where Stocks Yield 26% a Year (Ad)pixel
Disney (NYSE: DIS) Shares Just Gave Investors A Massive Signal
Solar Stocks Shine Brightly After Passage Of Clean Energy Bill
Large And Small Oil-And-Gas Stocks See Post-Earnings Bounce
One Stock Is All You Need  (Ad)pixel
S&P 500   4,207.27
DOW   33,336.67
QQQ   324.08
Find and Profitably Trade Stocks at 52-Week Lows
Average 126% gains – NO losers!?   (Ad)pixel
Why Invest in High-Yield Dividend Stocks?
The 2 Dow Stocks with Decade-Long Win Streaks on the Line
3 Stable Growth Stocks for Bumpy Times
27 U.S. Cities Where Stocks Yield 26% a Year (Ad)pixel
Disney (NYSE: DIS) Shares Just Gave Investors A Massive Signal
Solar Stocks Shine Brightly After Passage Of Clean Energy Bill
Large And Small Oil-And-Gas Stocks See Post-Earnings Bounce
One Stock Is All You Need  (Ad)pixel
NASDAQ:ALNY

Alnylam Pharmaceuticals - ALNY Stock Forecast, Price & News

$229.39
-2.61 (-1.13%)
(As of 08/11/2022 12:00 AM ET)
Add
Compare
Today's Range
$228.00
$234.51
50-Day Range
$127.70
$232.00
52-Week Range
$117.58
$234.51
Volume
735,386 shs
Average Volume
899,633 shs
Market Capitalization
$27.53 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$227.29

Alnylam Pharmaceuticals MarketRank™ Forecast

Analyst Rating
Moderate Buy
2.71 Rating Score
Upside/​Downside
0.9% Downside
$227.29 Price Target
Short Interest
Healthy
4.11% of Shares Sold Short
Dividend Strength
N/A
Sustainability
-1.52
Upright™ Environmental Score
News Sentiment
0.56mentions of Alnylam Pharmaceuticals in the last 14 days
Based on 30 Articles This Week
Insider Trading
Selling Shares
$1.03 M Sold Last Quarter
Proj. Earnings Growth
Growing
From ($8.14) to ($4.53) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.06 out of 5 stars

Medical Sector

592nd out of 1,112 stocks

Pharmaceutical Preparations Industry

302nd out of 544 stocks

ALNY stock logo

About Alnylam Pharmaceuticals (NASDAQ:ALNY) Stock

Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. The company's pipeline of investigational RNAi therapeutics focuses on genetic medicines, cardio-metabolic diseases, hepatic infectious diseases, and central nervous system (CNS)/ocular diseases. Its marketed products include ONPATTRO (patisiran), a lipid complex injection for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria (AHP); and OXLUMO (lumasiran) for the treatment of primary hyperoxaluria type 1 (PH1). In addition, the company is developing givosiran for the treatment of adolescent patients with AHP; patisiran for the treatment of transthyretin amyloidosis, or ATTR amyloidosis, with cardiomyopathy; cemdisiran to treat complement-mediated diseases; ALN-AAT02 for the treatment of AAT deficiency-associated liver disease; ALN-HBV02 to treat chronic HBV infection; Zilebesiran to treat hypertension; and ALN-HSD to treat NASH. Further, it offers Fitusiran for the treatment of hemophilia and rare bleeding disorders, Inclisiran to treat hypercholesterolemia, lumasiran for the treatment of advanced PH1 and recurrent renal stones, and vutrisiran for the treatment of ATTR amyloidosis, which is in phase 3 clinical trial. Alnylam Pharmaceuticals, Inc. has strategic collaborations with Regeneron Pharmaceuticals, Inc. to discover, develop, and commercialize RNAi therapeutics for a range of diseases by addressing therapeutic targets expressed in the eye and CNS; and Sanofi Genzyme to discover, develop, and commercialize RNAi therapeutics. It also has license and collaboration agreements with Novartis AG; Vir Biotechnology, Inc.; Dicerna Pharmaceuticals, Inc.; Ionis Pharmaceuticals, Inc.; and PeptiDream, Inc. The company was founded in 2002 and is headquartered in Cambridge, Massachusetts.

Wall Street Analysts Forecast Growth

Several analysts recently commented on the company. Needham & Company LLC lifted their price objective on Alnylam Pharmaceuticals from $205.00 to $240.00 and gave the stock a "buy" rating in a report on Thursday, August 4th. Evercore ISI lifted their price objective on Alnylam Pharmaceuticals to $252.00 in a report on Tuesday. William Blair began coverage on Alnylam Pharmaceuticals in a research report on Tuesday, June 7th. They set an "outperform" rating on the stock. SVB Leerink lifted their target price on Alnylam Pharmaceuticals from $96.00 to $98.00 and gave the company a "market perform" rating in a research report on Wednesday, June 15th. Finally, HC Wainwright lifted their target price on Alnylam Pharmaceuticals from $400.00 to $430.00 in a research report on Monday, May 2nd. Six equities research analysts have rated the stock with a hold rating and twelve have given a buy rating to the company's stock. Based on data from MarketBeat, the company currently has an average rating of "Moderate Buy" and a consensus target price of $227.29.

Alnylam Pharmaceuticals Stock Performance

Shares of ALNY opened at $232.00 on Thursday. Alnylam Pharmaceuticals has a 12 month low of $117.58 and a 12 month high of $233.88. The stock has a fifty day moving average price of $151.41 and a 200-day moving average price of $149.86. The company has a current ratio of 3.76, a quick ratio of 3.62 and a debt-to-equity ratio of 3.85. The firm has a market cap of $27.85 billion, a PE ratio of -28.40 and a beta of 0.74.

Alnylam Pharmaceuticals (NASDAQ:ALNY - Get Rating) last issued its quarterly earnings data on Thursday, July 28th. The biopharmaceutical company reported ($2.29) EPS for the quarter, missing the consensus estimate of ($1.62) by ($0.67). Alnylam Pharmaceuticals had a negative net margin of 110.91% and a negative return on equity of 204.18%. The business had revenue of $224.80 million for the quarter, compared to analysts' expectations of $256.06 million. During the same quarter in the prior year, the company posted ($1.61) EPS. The business's revenue for the quarter was up 1.9% on a year-over-year basis. Equities research analysts predict that Alnylam Pharmaceuticals will post -8.14 earnings per share for the current fiscal year.

Insider Activity at Alnylam Pharmaceuticals

In related news, EVP Tolga Tanguler sold 1,841 shares of the company's stock in a transaction on Friday, August 5th. The stock was sold at an average price of $218.16, for a total value of $401,632.56. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Insiders have sold a total of 5,349 shares of company stock valued at $1,033,073 in the last ninety days. Company insiders own 1.40% of the company's stock.

Receive ALNY Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Alnylam Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

ALNY Stock News Headlines

Alnylam Pharmaceuticals (NASDAQ:ALNY) PT Raised to $192.00
Alnylam Pharmaceuticals (NASDAQ:ALNY) PT Raised to $240.00
Alnylam Pharmaceuticals (NASDAQ:ALNY) PT Raised to $225.00
See More Headlines
Receive ALNY Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Alnylam Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

ALNY Company Calendar

Last Earnings
7/28/2022
Today
8/12/2022
Next Earnings (Estimated)
10/27/2022
Fiscal Year End
12/31/2022

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
Biotechnology
Sector
Medical
Current Symbol
NASDAQ:ALNY
CUSIP
02043Q10
Employees
1,665
Year Founded
2002

Price Target and Rating

Average Stock Price Forecast
$227.29
High Stock Price Forecast
$430.00
Low Stock Price Forecast
$98.00
Forecasted Upside/Downside
-0.9%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.71
Research Coverage
17 Analysts

Profitability

Net Income
$-852,820,000.00
Net Margins
-110.91%
Pretax Margin
-110.67%

Debt

Sales & Book Value

Annual Sales
$844.29 million
Book Value
$1.47 per share

Miscellaneous

Free Float
118,347,000
Market Cap
$27.53 billion
Optionable
Optionable
Beta
0.74

Social Links


Key Executives

  • Mr. Michael W. Bonney B.A. (Age 64)
    Exec. Chairman
    Comp: $317.97k
  • Dr. Yvonne L. Greenstreet M.B.A. (Age 59)
    MBA, MBChB, CEO & Director
    Comp: $1.23M
  • Dr. Akshay K. Vaishnaw M.D. (Age 59)
    Ph.D., Pres
    Comp: $1.09M
  • Mr. Jeffrey V. Poulton M.B.A. (Age 54)
    CFO & Exec. VP
    Comp: $914.05k
  • Mr. Tolga Tanguler M.B.A.
    Exec. VP & Chief Commercial Officer
  • Dr. Alfred W. Boyle Ph.D.
    Chief Technical Operations & Quality Officer
  • Dr. Kevin Joseph Fitzgerald Ph.D. (Age 54)
    Sr. VP, Head of Research & Chief Scientific Officer
  • Ms. Christine Regan Lindenboom
    Sr. VP of Investor Relations & Corp. Communications
  • Ms. Indrani M. Lall Franchini J.D. (Age 50)
    Exec. VP, Chief Legal Officer & Sec.
  • Mr. Mark Baglin
    VP of Global Marketing













ALNY Stock - Frequently Asked Questions

Should I buy or sell Alnylam Pharmaceuticals stock right now?

17 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Alnylam Pharmaceuticals in the last year. There are currently 5 hold ratings and 12 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" ALNY shares.
View ALNY analyst ratings
or view top-rated stocks.

What is Alnylam Pharmaceuticals' stock price forecast for 2022?

17 equities research analysts have issued 1-year target prices for Alnylam Pharmaceuticals' shares. Their ALNY share price forecasts range from $98.00 to $430.00. On average, they predict the company's share price to reach $227.29 in the next twelve months. This suggests that the stock has a possible downside of 0.9%.
View analysts price targets for ALNY
or view top-rated stocks among Wall Street analysts.

How have ALNY shares performed in 2022?

Alnylam Pharmaceuticals' stock was trading at $169.58 at the beginning of the year. Since then, ALNY stock has increased by 35.3% and is now trading at $229.39.
View the best growth stocks for 2022 here
.

When is Alnylam Pharmaceuticals' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, October 27th 2022.
View our ALNY earnings forecast
.

How were Alnylam Pharmaceuticals' earnings last quarter?

Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) released its earnings results on Thursday, July, 28th. The biopharmaceutical company reported ($2.29) EPS for the quarter, missing analysts' consensus estimates of ($1.62) by $0.67. The biopharmaceutical company earned $224.80 million during the quarter, compared to the consensus estimate of $256.06 million. Alnylam Pharmaceuticals had a negative trailing twelve-month return on equity of 204.18% and a negative net margin of 110.91%. The firm's quarterly revenue was up 1.9% compared to the same quarter last year. During the same period in the prior year, the firm posted ($1.61) earnings per share.

What guidance has Alnylam Pharmaceuticals issued on next quarter's earnings?

Alnylam Pharmaceuticals issued an update on its FY 2022 earnings guidance on Thursday, August, 4th. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $870.00 million-$930.00 million, compared to the consensus revenue estimate of $1.09 billion.

What is John M. Maraganore's approval rating as Alnylam Pharmaceuticals' CEO?

65 employees have rated Alnylam Pharmaceuticals Chief Executive Officer John M. Maraganore on Glassdoor.com. John M. Maraganore has an approval rating of 99% among the company's employees. This puts John M. Maraganore in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Alnylam Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Alnylam Pharmaceuticals investors own include Alibaba Group (BABA), NVIDIA (NVDA), XOMA (XOMA), Ionis Pharmaceuticals (IONS), Gilead Sciences (GILD), NXP Semiconductors (NXPI), Mylan (MYL), AbbVie (ABBV), Micron Technology (MU) and Advanced Micro Devices (AMD).

What is Alnylam Pharmaceuticals' stock symbol?

Alnylam Pharmaceuticals trades on the NASDAQ under the ticker symbol "ALNY."

Who are Alnylam Pharmaceuticals' major shareholders?

Alnylam Pharmaceuticals' stock is owned by a number of retail and institutional investors. Top institutional investors include Baillie Gifford & Co. (8.31%), Loomis Sayles & Co. L P (0.69%), Pictet Asset Management SA (0.57%), Artal Group S.A. (0.50%), Swiss National Bank (0.43%) and Mitsubishi UFJ Trust & Banking Corp (0.39%). Insiders that own company stock include Akshay Vaishnaw, Barry E Greene, Jeffrey W Dunn, John Maraganore, Laurie Keating, Marsha Fanucci, Phillip A Sharp, Steven M Paul, Tolga Tanguler and Yvonne Greenstreet.
View institutional ownership trends
.

How do I buy shares of Alnylam Pharmaceuticals?

Shares of ALNY stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Alnylam Pharmaceuticals' stock price today?

One share of ALNY stock can currently be purchased for approximately $229.39.

How much money does Alnylam Pharmaceuticals make?

Alnylam Pharmaceuticals (NASDAQ:ALNY) has a market capitalization of $27.53 billion and generates $844.29 million in revenue each year. The biopharmaceutical company earns $-852,820,000.00 in net income (profit) each year or ($8.17) on an earnings per share basis.

How many employees does Alnylam Pharmaceuticals have?

The company employs 1,665 workers across the globe.

When was Alnylam Pharmaceuticals founded?

Alnylam Pharmaceuticals was founded in 2002.

How can I contact Alnylam Pharmaceuticals?

Alnylam Pharmaceuticals' mailing address is 675 WEST KENDALL STREET HENRI A. TERMEER SQUARE, CAMBRIDGE MA, 02142. The official website for the company is www.alnylam.com. The biopharmaceutical company can be reached via phone at (617) 551-8200, via email at investors@alnylam.com, or via fax at 617-551-8101.

This page (NASDAQ:ALNY) was last updated on 8/12/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | contact@marketbeat.com | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Privacy Policy | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see Barchart's disclaimer.